Discovery of (S)-N-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6H)-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate-Reference-Cited by-同舟云学术

Discovery of (S)-N-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6H)-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate

Published:2023-05-15 Issue:10 Volume:66 Page:7016-7037
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Li Daqiang¹,Zhang Zhuo¹²³,Li Yalei⁴,Wang Xinyi⁴³,Zhong Hanyue¹³,Yang Huajie¹,Xi Yong⁴,Liu Hongchun⁴,Shen Aijun⁴³⁵,Hu Youhong¹²³⁶^ORCID

Affiliation:

1. State Key Laboratory of Drug Research, Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China

2. School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China

3. University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 110039, China

4. Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, No. 555 Zu-Chong-Zhi Road, Shanghai 201203, China

5. Lingang Laboratory, Shanghai 200031, China

6. School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, UCAS, Hangzhou 310024, China

Funder

Science and Technology Commission of Shanghai Municipality

National Natural Science Foundation of China

Chinese Academy of Sciences

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00525